Atenolol versus propranolol for the treatment of infantile hemangiomas: A randomized controlled study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:70

Article

Abarzua-Araya, Alvaro¹  Navarrete-Dechent, Cristian P.¹  Heusser, Felipe²  Retamal, Javiera²  Soledad Zegpi-Trueba, Maria¹ 

[1] Pontificia Univ Catolica Chile, Fac Med, Dept Dermatol, Santiago, Chile

[2] Pontificia Univ Catolica Chile, Fac Med, Dept Pediat Cardiol, Santiago, Chile

关键词: atenolol;    beta-blockers;    hemangiomas;    propranolol;    randomized;    treatment;    trial;   

DOI  :  10.1016/j.jaad.2014.01.905

来源: Elsevier

【 摘 要 】

Background: Infantile hemangiomas have a dramatic response to propranolol, a nonselective beta-blocker. However, this treatment is not risk-free and many patients are excluded because of respiratory comorbidities. Atenolol is a cardioselective beta-blocker that may have fewer adverse events. Objective: We sought to evaluate the effectiveness of atenolol against propranolol in a noninferiority trial. Methods: In all, 23 patients met the inclusion criteria and were randomized to receive either atenolol or propranolol. Thirteen patients were treated with atenolol and 10 with propranolol. Follow-up was made at baseline, 2 weeks, 4 weeks, and then monthly for 6 months. Results: Patients treated with atenolol had a complete response of 53.8% and 60% with propranolol, respectively. These results were nonsignificant (P = .68). Relevant adverse events were not reported. Limitations: The reduced number of patients could have influenced our results. Conclusion: Atenolol appears to be as effective as propranolol. We did not find significant differences between these results or any adverse events.

【 授权许可】

Free